Bafna Pharmaceuticals Ltd vs Windlas Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 131.85 as of 05 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2022 to 35.8 on March 2025 . This represents a CAGR of 31.42% over 4 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2022 to ₹ 2176 crore on March 2025 . This represents a CAGR of 47.65% over 4 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Windlas Biotech Ltd for the Dec '25 is ₹ 237.67 crore as compare to the Sep '25 revenue of ₹ 226.04 crore. This represent the growth of 5.15% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Windlas Biotech Ltd for the Dec '25 is ₹ 28.95 crore as compare to the Sep '25 ebitda of ₹ 32.2 crore. This represent the decline of -10.09% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Windlas Biotech Ltd changed from ₹ 13.48 crore to ₹ 15 crore over 7 quarters. This represents a CAGR of 6.30% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2022 to 20.04 % on March 2025 . This represents a CAGR of 0.31% over 4 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Windlas Biotech Ltd

Windlas Biotech Limited, formerly known as Windlas Biotech Private Limited was incorporated in 2001.
The Company got converted from a Private Limited to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'.
A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun. The Company is engaged in manufacturing and trading of pharmaceutical products.
Their manufacturing plants are located at Dehradun in Uttarakhand.
It has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The Company commenced operations at Dehradun Plant -IV in 2010.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Windlas Biotech Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Windlas Biotech Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 324 Cr while Market cap of Windlas Biotech Ltd is 1,811 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Windlas Biotech Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Windlas Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Windlas Biotech Ltd?

As of May 5, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹137.0. On the other hand, Windlas Biotech Ltd stock price is INR ₹858.1.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Windlas Biotech Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Windlas Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.